News & Perspective

Oct 13, 2005

Oct 13, 2005

Tests confirm H5N1 in Turkey, H5 in Romania

(CIDRAP News) – The avian influenza virus long established in Southeast Asia has reached Europe's doorstep, with confirmation today that a lethal virus in Turkey is H5N1 and that an H5 strain in Romania is still being subtyped.

May 09, 2007

May 09, 2007

EU approves Novartis's 'mock-up' pandemic vaccine

(CIDRAP News) – The European Union (EU) this week approved a "mock-up" influenza vaccine made by Novartis to permit a faster start on vaccine production in the event of a flu pandemic.

Jun 13, 2007

Jun 13, 2007

EU approves Novartis's cell-based flu vaccine

(CIDRAP News) – The European Union (EU) has approved Novartis's seasonal influenza vaccine, Optaflu, putting the Swiss company in a position to become the first to market a flu vaccine grown in cell culture rather than eggs.

Oct 25, 2007

Oct 25, 2007

THE PANDEMIC VACCINE PUZZLE Bibliography

Editor's note: This is the bibliography to a seven-part series launched October 25, 2007, investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

May 19, 2008

May 19, 2008

EU approves its first prepandemic H5N1 vaccine

(CIDRAP News) – An H5N1 influenza vaccine made by the British pharmaceutical company GlaxoSmithKline (GSK) has become the first prepandemic vaccine to be licensed by the European Union (EU), the company announced today.

Jun 12, 2008

Jun 12, 2008

Baxter says cell-based H5N1 vaccine did well in trial

(CIDRAP News) – A pharmaceutical company is reporting good results in the first clinical trial of an H5N1 avian influenza vaccine that uses a whole, killed H5N1 virus grown in cell culture—a combination of techniques that entails some risk but may boost immune response and shorten production time.

Jun 17, 2008

Jun 17, 2008

Australia approves CSL's H5N1 vaccine

(CIDRAP News) – Australian authorities have approved an H5N1 avian influenza vaccine made by the Australian-based pharmaceutical company CSL Limited, giving the country a home-grown defensive tool if the virus evolves into a pandemic strain.

Dec 22, 2008

Dec 22, 2008

EU panel supports innovative pandemic, seasonal flu vaccines

(CIDRAP News) – An H5N1 influenza vaccine made by Baxter International could become the first cell culture–based H5N1 influenza vaccine to be approved for marketing, following its endorsement by a committee of the European Medicines Agency (EMEA) last week.

Recommendations of the Committee for Medicinal Products for Human Use (CHMP) are usually followed by the EMEA within a few months.

Feb 26, 2009

Feb 26, 2009

Europe approves Sanofi's intradermal flu vaccine

Editor's note: This story was updated Feb 27 to include more information about an intradermal vaccine that Sanofi Pasteur is developing for the US market.

(CIDRAP News) – The European Union has approved the first influenza vaccine injected with a shallow needle prick into the skin instead of a jab all the way into muscle, according to Sanofi Pasteur, the vaccine's manufacturer.

Pages

Sort Results

 

Narrow results

by Topic

by country

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3M Gilead 
Grant support for ASP provided by

  Become an underwriter»